A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
about
Antiangiogenic therapy in breast cancer.Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.Immunotherapeutic interventions of Triple Negative Breast Cancer.Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study
P2860
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
A Real-World Multicentre Retro ...... tive Metastatic Breast Cancer.
@en
A Real-World Multicentre Retro ...... tive Metastatic Breast Cancer.
@nl
type
label
A Real-World Multicentre Retro ...... tive Metastatic Breast Cancer.
@en
A Real-World Multicentre Retro ...... tive Metastatic Breast Cancer.
@nl
prefLabel
A Real-World Multicentre Retro ...... tive Metastatic Breast Cancer.
@en
A Real-World Multicentre Retro ...... tive Metastatic Breast Cancer.
@nl
P2093
P2860
P50
P356
P1476
A Real-World Multicentre Retro ...... ative Metastatic Breast Cancer
@en
P2093
Alessandra Cassano
Alessandra Fabi
Andrea Michelotti
Angela Vaccaro
Antonino Astone
Antonino Grassadonia
Arianna Pellegrino
Cecilia Nisticò
Claudia De Angelis
Domenica Pellegrini
P2860
P304
P356
10.1002/JCP.25685
P50
P577
2016-11-30T00:00:00Z